Abbvie approved. Gilead is toast

[Anonymous]

Was a good run, Gilead! There is a new sheriff in town.

 

[Anonymous]

More like toast points with caviar dip shit! We do not fear you loosers. You are the Chicago Cubs of Pharma.

 

[Anonymous]

Was a good run, Gilead! There is a new sheriff in town.

Gilead is in deep trouble. It was def. a nice run while it lasted, though.

 

[Anonymous]

Gilead is in deep trouble. It was def. a nice run while it lasted, though.

Why would you use a drug for 12 weeks for 83,319 when you can use Harvoni for $63,000?
Toast? Not so much

 

[Anonymous]

Why would you use a drug for 12 weeks for 83,319 when you can use Harvoni for $63,000?
Toast? Not so much

Exactly! Could be as many as 60-80% of patients may be eligible for 8wks.

 

[Anonymous]

Was a good run, Gilead! There is a new sheriff in town.

Obviously u lack insights....having two products will cause expansion of the market and so more revenue and slower growth for GILD. So market share will be shared....101 marketing.

 

[Anonymous]

Obviously u lack insights....having two products will cause expansion of the market and so more revenue and slower growth for GILD. So market share will be shared....101 marketing.

What a dope! More revenue and slower growth! U my friend are a r*****. Managed care will dictate market forces. Even at the prices quoted and discounts applied growth will be fairly steady for the next 10 years. The market can handle about 400k patients per year. He who has the best market share based on coverage, physician support and AASLD recomendations wins. Most Wall Street analysts have GILD at a 80% share. So shove your marketing 101 analogy up your ass. It's economics and finance douche.

 

[Anonymous]

What a dope! More revenue and slower growth! U my friend are a r*****. Managed care will dictate market forces. Even at the prices quoted and discounts applied growth will be fairly steady for the next 10 years. The market can handle about 400k patients per year. He who has the best market share based on coverage, physician support and AASLD recomendations wins. Most Wall Street analysts have GILD at a 80% share. So shove your marketing 101 analogy up your ass. It's economics and finance douche.

Bu, bu, but management here at Abbie said patients and doctors will prefer our drug because what's better than starting and ending your day with a cereal bowl of pills.

 

[Anonymous]

Was a good run, Gilead! There is a new sheriff in town.

Fellow Gileadians: Why argue with an Abbvie rep that is probably in their 20's and excited to have their first real job. Mark Twain said it best . . . "Never argue with an idiot . . . they will drag you down to their level and beat you with experience."

 

[Anonymous]

What a dope! More revenue and slower growth! U my friend are a r*****. Managed care will dictate market forces. Even at the prices quoted and discounts applied growth will be fairly steady for the next 10 years. The market can handle about 400k patients per year. He who has the best market share based on coverage, physician support and AASLD recomendations wins. Most Wall Street analysts have GILD at a 80% share. So shove your marketing 101 analogy up your ass. It's economics and finance douche.

ur birth was a douche u scum bag!

 

[Anonymous]

Good morning my former HCV friends, I hope you've enjoyed your time as the king of the hill, with the decision by ESI to make Viekira combo of choice, your arrogance at being willing to negotiate within the US (outside your willing to give your shit away as good PR, just knowing that the US market is paying for it) has come to fruition. May the games begin.......now you'll have to learn how to sell and not use your smoozing BS to gain favoritism.

 

[Anonymous]

Uh oh...Nobody likes to get into a pricing pissing match. Will be fun to sit back and watch this unfold...GILD in pre market down -10.33...ouchy. Hello Express Scipts...can I have another?

 

[Anonymous]

Was a good run, Gilead! There is a new sheriff in town.

Lets call it what it really is.....Bait and Switch program disguised as an ACCESS to HEP C Patients

 

[Anonymous]

Lets call it what it really is.....Bait and Switch program disguised as an ACCESS to HEP C Patients

John Martin must be freakin out that his billion dollar worth is down a bit.

 

[Anonymous]

waaaaaaaaaaaaaa!

Mommy!!!!!!!!!

learn how payors operate on your next launch

 

[Anonymous]

Must say, if GILD got caught flat-footed on this one, shame on them.

They are an incredibly arrogant lot, with the most arrogant of all being their lawyers. Wonder what strategy they'll opt for in attempting to fight back.

 

[Anonymous]

Must say, if GILD got caught flat-footed on this one, shame on them.

They are an incredibly arrogant lot, with the most arrogant of all being their lawyers. Wonder what strategy they'll opt for in attempting to fight back.

I am the OP. I waited until today to see how many posters would shoot me down, and I wasn't shocked at the arrogance I saw. And I knew I would get the last laugh.

 

[Anonymous]

Settle down. Your big discount might help you get to about 10-15% SOM... I'll take 85% and $10-12 billion in 2015.

 

[Anonymous]

Settle down. Your big discount might help you get to about 10-15% SOM... I'll take 85% and $10-12 billion in 2015.

Ha! Ha! We are COMING FOR 100% share, you Gilead slime ball!!!!! I guess your CEO is no longer a billionaire!!! Bawhahahahahaha!!

 

[Anonymous]

Ha! Ha! We are COMING FOR 100% share, you Gilead slime ball!!!!! I guess your CEO is no longer a billionaire!!! Bawhahahahahaha!!

Yes you are right. He's worth billions. And named CEO of the year. We are ready for you clowns and your silly drug. Don't bring a knife to a gun fight! Or in your case a butter knife.